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Abstract 
 
Numerous studies have indicated that dysregulation of the immune system occurs 
during or after spaceflight. Using 21 day -6º head-down tilt bed rest as a spaceflight 
analog, this study describes the effects of artificial gravity (AG) as a daily 
countermeasure on immunity, stress and reactivation of clinically important latent 
herpes viruses. The specific aims were to evaluate psychological and physiological 
stress, to determine the status of the immune system, and to quantify reactivation of 
latent herpes viruses. Blood, saliva, and urine samples were collected from each 
participating subject at different times throughout the study. An immune assessment 
was performed on all treatment and control subjects that consisted of a 
comprehensive peripheral immunophenotype analysis, intracellular cytokine profiles 
and a measurement of T cell function.   The treatment group displayed no differences 
throughout the course of the study with regards to peripheral leukocyte distribution, 
cytokine production or T cell function.  Shedding of Epstein barr virus (EBV), 
Cytomegalovirus (CMV), and Varicella zoster virus (VZV) was quantified by real 
time PCR in saliva and urine samples, respectively. There was no significant 
difference in CMV DNA in the treatment group as compared to the control group. 
EBV and VZV on the other hand showed a mild reactivation during the study. There 
were no significant differences in cortisol between the control and treatment groups. 
In addition, no significant differences between antiviral antibody titers (EBV-VCA, -
EA, -EBNA, CMV) or tetramer-positive (EBV, CMV) were found between the two 
groups. EBV DNA copies in blood were typically undetectable but never exceeded 
1,500 copies per 106 PBMCs. Overall, these data indicate that the artificial gravity 
countermeasure and the 21 day head-down tilt bed rest regimen had no observable 
adverse effect on immune function.   
 
Introduction 
 
Space flight is a unique experience and results in adverse effects on human 
physiology.  Changes have been reported in the musculoskeletal, neurovestibular, 
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cardiovascular, endocrine, and immune systems as well as others (12). As NASA 
goes forward, preparing for longer exploration missions to the Moon, Mars, and 
eventually beyond, effective countermeasures to these adverse effects on humans 
must be developed, verified, and implemented to ensure mission success. Many of the 
significant adverse effects of space flight on human physiology are caused by various 
stressors.  These include isolation, confinement, anxiety, sleep deprivation, 
psychosocial interactions, and physical exertion. The physical environment further 
subjects the crew to noise, chemical and microbiological contaminants, increased 
radiation, and variable gravity forces (hyper- and hypo-gravity).  Many of these stress 
factors are intermittent, but some are relatively constant (such as microgravity on 
long missions).   
 
Research on astronaut physiology in space is complicated by exposure to these and 
other uncontrolled factors.  Research is further slowed by the limited access to space 
and availability of microgravity-compatible technology for on-board analyses.  For 
these reasons, high-fidelity ground-based analogs of space flight are essential tools 
for studying the effects of space flight on human physiology, developing 
countermeasures as needed, and testing the efficacy of countermeasures.   
 
Various ground-based analogs have been developed and used to model specific 
aspects of space flight.  Bed rest has been successfully used to model the effects of 
microgravity on musculoskeletal and some other physiological systems. The immune 
system is affected by space flight, and some analogs have been used to study various 
aspects of immunity at the cellular level. Some success in studying the effects of 
space flight on the immune system has also been achieved in specific animal models 
(8, 13). Stress models such as Antarctic science stations and others have been useful 
in study of the effect of stress on human immunity (14). Generally, human bed rest 
has not been demonstrated to be a highly useful model for human immunity studies.  
However, the use of artificial gravity (AG) as a countermeasure for some other 
physiological systems (e.g., musculoskeletal) may impact some elements of 
immunity. The immune system interacts with most if not all other physiological 
systems.  From this perspective, measuring selected indicators of immune status 
makes a valuable contribution to the overall study of efficacy of artificial gravity as a 
countermeasure for other physiological systems. In the current study, we tested the 
combined effects of hypergravity and stress and other factors associated with bed rest 
on changes in immunity and reactivation of latent herpes viruses.  
 
Methods 
 
Fifteen human subjects completed the study.  All subjects spent 41 days residing in 
the NIH-supported General Clinical Research Center (GCRC) located at the 
University of Texas Medical Branch (UTMB) in Galveston, TX and were 
deconditioned by 6o head-down tilt bed rest for 21 of those days.  Subjects in the 
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Treatment group (n=8) received one hour of AG via centrifugation daily.  Subjects in 
the Control group (n=7) did not receive any countermeasure. All human study 
protocols were approved by the Committee for the Protection of Human Subjects of 
the Johnson Space Center, Houston, TX, and informed consent were obtained from 
all subjects.  
 
Blood, saliva, and urine samples were collected from each participating subject in this 
study according to the schedule shown in Figure 1. Simultaneously, psychological 
stress was measured in each subject at the time of saliva collection using a 
questionnaire (figure 1). Blood samples were used to measure concentrations of stress 
hormones and titers of antibodies to viruses and to conduct tests of immune system 
status, including measurement of virus-specific T-cell number and function. Shedding 
of viral DNA was quantified in saliva and urine samples, and urine samples were 
used to measure excretion of stress hormones. 
 
Psychological Stress 
Psychological stress was measured by asking each participating subject to complete 
two questionnaires, the Perceived Stress Scale (PSS) and the Positive Affect and 
Negative Affect Scale (PANAS). These questionnaires were completed first thing in 
the morning, on days before, during, and after the subjects’ saliva was collected. The 
questionnaires were scored and data were analyzed statistically.  
 
The 10-item PSS (1) was used to measure the extent to which participants perceived 
their recent life circumstances as stressful (that is, unpredictable, uncontrollable, and 
overloading).  Participants rate each of the 10 statements on a 5-point scale (0 = never 
to 4 = very often), so that scores range from 0 to 40.  The scale is internally consistent 
and has demonstrated moderate correlations with other measures of appraised stress 
(15). 
 
Physiological Stress  
Plasma and salivary cortisol measurements were done by methods previously 
described (9). 
Immune System Status 
 
Immunophenotype analysis 
A moderate four-color flow cytometry antibody matrix was created that assessed all 
the major leukocyte/lymphocyte subsets, as well as activated and memory/naïve T 
cell subsets.   Cell surface markers were stained first combining 100 ul of EDTA 
whole blood and 10 μg of each appropriate labeled monoclonal antibodies.   Staining 
was performed by incubated at room temperature for 20 minutes.   Red blood cells 
were lysed using Beckman-Coulter optilyse as described by the manufacturer.  
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Stained leukocytes were then fixed in 1.0% paraformaldehyde in PBS for 10 minutes 
and analyzed on a Beckman-Coulter Epics XL flow cytometer.  The cytometry panel 
is outlined in table 1 (Brian, please change the Table number from 2 to 1).  The 
white blood cell count (WBC) and differential were performed at the indicated 
timepoints by the Johnson Space Center clinical laboratory using a Beckman-Coulter 
Hematology Analyzer.   
 
Intracellular cytokine analysis   
Lymphocyte and monocyte cytokine production were assessed for specific cell 
subsets at the single-cell level utilizing intracellular flow cytometry.  The unique 
advantage of intracellular flow cytometry is the ability to assess the production of 
multiple cytokines simultaneously in positively identified cell sub-populations using 
multi-color flow cytometry.   Whole blood cultures were set up by adding 100 ul 
heparin whole blood to 1.0 culture media containing 10 ng/ml PMA, 1.0 ug/ml 
ionomycin and 3 uM monensin.  Cultures were incubated for 4.0 hours at 37 degrees 
C.   Following incubation, the supernatants were removed, the RBCs lysed as noted 
above, and the remaining WBCs were fixed in 4.0% paraformaldehyde for 10 
minutes.   To detect intracellular production of IFNγ or IL-2 (following surface 
marker staining), the fixed PBMC's were resuspended in 200 μl of permeabilization 
buffer, consisting of 5.0% non-fat dry milk and 0.5% saponin in PBS to which 0.5 μg 
of labeled mouse antibody to either IFNγ or IL-2 (or both) was added.   The cells 
were incubated at room temperature for 25 minutes and then washed in PBS 
containing saponin.  The cells were then resuspended in 1.0% paraformaldehyde for 
analysis.  
 
T cell function 
Immune suppression may consist of a reduced capacity for lymphocytes to respond to 
stimulus, even though the relative distribution of immune cells is unchanged.  For this 
study the functional response of T cells was measured by activating whole blood 
cultures in the presence of T cell mitogenic stimuli, followed by measurement of 
surface activation marker expression on T cell subsets.  Culture in the presence of 
anti-CD3 and anti-CD28 antibodies was used for T cell stimulation.  These antibodies 
activate T cells by triggering T cell surface molecules, requiring the full compliment 
of intracellular signaling to be utilized (as opposed to phorbol ester or ionomycin).  T 
cell progression through a full activation cycle may be monitored by culturing cells 
for 24 hours and determining the expression of cell surface CD69 (early activation), 
CD25 (mid-activation, receptor for IL-2 that requires new gene synthesis).  
 
Tetramer assay 
HLA-A*0201-restricted tetramers (EBV BMLF; CMV pp65) were obtained from 
Beckman Coulter (San Diego, CA). PBMCs were incubated with PE- or APC-labeled 
MHC-tetramer complexes, along with CD8-PerCP (BD Biosciences), in dPBS with 
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2% FCS for 30 minutes at room temperature. Cells were then washed and fixed in 1% 
PFA and analyzed on a FACSCalibur flow cytometer using CellQuest software for 
data collection and analysis.  
 
Peptide stimulation assay   
Intracellular cytokine staining assays were performed as described elsewhere (2, 4). 
PBMCs were isolated from heparinized whole blood by density-gradient 
centrifugation and washed three times in Dulbecco’s phosphate-buffered saline 
(dPBS) prior to use in functional studies. PBMCs were used immediately and 
stimulated with HLA-A*0201-restricted epitopic peptides (10 ug/ml/peptide), 
controls (PBS) or staphylococcus enterotoxin B (SEB) (10 ug/mL). Peptides used in 
this study were CMV pp65 (residues 495-503; NLVPMVATV) and EBV BMLF 
(residues 280-288; GLCTLVAML). Costimulatory monoclonal antibodies (mAbs) – 
CD28 and CD49d mAbs (1 ug/ml each) (BD Immunocytometry Systems) – were 
added to each tube. The tubes were vortexed and incubated for 6 h at 37ºC with 5% 
CO2, with the addition of Brefeldin A (10 ug/ml; Sigma) for the last 5 h. Following 
stimulation, cells were washed in PBS, incubated for 5 min at 37ºC in 0.02% EDTA 
and washed in dPBS. Cells were then sequentially incubated for 10 minutes in 
FACSLyse and FACSPerm solutions (both from Becton-Dickinson Biosciences), 
washed, and stained with anti-IFN-γ (PE), anti-TNF-a (FITC), anti-CD8 (PerCP), and 
anti-CD69 (APC) antibodies. Samples were then fixed in 1% paraformaldehyde and 
analyzed by four-color flow cytometry using a FACSCalibur cytometer and 
CellQuest software (both BD Biosciences).  
 
Viral Reactivation Assessment 
 
Viral DNA by polymerase chain reaction   
PCR was performed on either urine, saliva, or 1x106 peripheral blood mononuclear 
cells.  3.0 ml of each urine sample or 2.0 ml of saliva was concentrated to ~200 uL by 
centrifugation using a Microsep concentrator 100K (Pall Filtron Corp., 
Northborough, MA). Extraction of genomic/viral DNA from concentrated urine was 
performed using the QIAamp Viral RNA Kit (Qiagen Inc., Santa Clarita, CA) 
according to the manufacturer’s instructions.   EBV and VZV DNA were quantitated 
by real-time PCR using an ABI 7700 sequence detector (3, 5, 7). CMV DNA was 
quantitated using the same methodology but with primers that targeted the immediate 
early gene (11).   
 
Plasma viral antibody levels   
Anti-viral antibody titers were determined by indirect immunofluorescence as 
previously described (7, 9, 10). Commercially prepared substrate slides and control 
sera (Bion Enterprises, Park Ridge, IL) were used for determining IgG antibody titers 
to EBV-viral capsid antigen (VCA) and early antigen (EA), EBV-nuclear antigen 
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(EBNA), VZV and CMV. Two-fold dilutions of plasma or serum from each subject 
were prepared, and the endpoint titer was determined as the highest dilution of serum 
still able to demonstrate immunofluorescence-positive cells. All specimens were 
batch analyzed and read blind-coded.  
 
 
Results 
 
Psychological and Physiological stress  
 
PSS and PANAS results 
A total of 318 behavioral measurements for Perceived Stress Scale (PSS) and Positive 
Affect and Negative Affect Scale (PANAS) scores were collected from all the 15 
subjects (8 treatment and 7 control subjects) during the 41 day period of the study.   
No significant differences were found in the PANAS, and PSS in these subjects 
during 21-day study as compared to the before bed rest values or between the control 
and treatment group (data not shown).  
 
Cortisol levels 
Salivary cortisol levels were measured in 7 control and 8 treatment subjects. No 
significant changes were observed between the treatment or control subjects or 
between the time intervals before, during or after the 21 day bed rest. Likewise with 
plasma cortisol levels, no significant differences were found either between or within 
the treatment or control groups.   
 
 
Immune assessment 
The peripheral immunophenotype was assessed for all control and treatment subjects 
and consisted of a leukocyte differential, lymphocyte subsets, and the following T 
cell subsets: CD4/CD8 ratio, memory/naïve (CD45RA+/-), early activated (CD69+) 
and late activated (HLA-DR+).   The control subjects displayed an elevated 
percentage of granulocytes that persisted over the duration of the head-down phase 
and resolved by R+9 (figure 2B), that was not observed in the treatment subjects 
(figure 2A) (p =0.6).   This change was not statistically significant.  In general, no 
other consistent differences were observed in the peripheral leukocyte distribution for 
any of the subsets measured for either the treatment or control subjects (figures 2A 
and 2B respectively).   Intracellular IFNγ and IL-2 were assessed for both the CD4+ 
and CD8+ T cell subsets following 5 hours stimulation with PMA+ionomycin.  The 
treatment subjects displayed a significant decrease in the CD4+/IFNγ+ subset and a 
non-significant trend towards reduced CD8+/IFNγ+ (figure 2C) at BR+7 as compared 
to baseline values.   This change was not evident in the control subjects.  In fact, the 
control subjects demonstrated an increase in CD4+/IFNγ percentage that was not 
Z:\adlib_out\to be loaded\JSC\13744.doc 6
significant (figure 2D).  There were no obvious mission associated changes observed 
for the CD4+/IL-2 and CD8+/IL-2 subsets.   T cell function was assessed by 
stimulating T cells with soluble CD3/CD28 antibodies for 24 hours and measuring 
the percentage of responding CD69+/CD25+ T cell subsets.  There appeared to be no 
observable alterations in T cell function for either the treatment (figure 2E) or the 
control (figure 2F) subjects.   
 
Four of the treatment subjects were HLA-A2 positive, while only 1 of the control 
subjects was positive. This limited data analysis for the MHC tetramers and peptide-
stimulation assays. However, no differences were found in the levels of either  CMV 
or EBV-specific CD8+ T-cells as revealed by MHC tetramer staining nor functional 
differences as determined by intracellular cytokine synthesis (IFN-γ and TNF-α) 
following viral-peptide stimulation (all data not shown). 
 
Viral Reactivation 
 
Antibody titers to EBV-VCA, -EA, EBNA, and CMV were measured in the control 
and treatment groups over the course of the study. No significant changes were found 
in any of the antiviral IgG antibodies between or within the 2 groups (data not 
shown).  
 
Salivary EBV was detected frequently in both control group and treatment group. 
However, its frequency and copy number did not change significantly between these 
two group or before, during and after the 21 day bed rest period. The frequency of 
VZV DNA was found in fewer of the saliva samples collected from treatment 
subjects than the samples from control. Similarly, CMV was also found less 
frequently in samples collected from treatment subjects as compared to the control 
subjects (Table 2). EBV DNA levels in peripheral blood PBMCs were also measured. 
The levels of EBV DNA were generally undectable and never exceeded 1,500 copies 
per 106 PBMCs; no differences were found between the 2 groups.  
 
Discussion 
 
 
As peripheral phenotypic changes are generally associated with subject pathology, it 
was not unexpected that there were essentially no peripheral phenotype alterations in 
both the treatment and control subjects.   This is consistent with healthy individuals 
who are essentially ‘isolated’ from society for a period of time.   We did not expect 
them to become ‘ill’.   However, data from spaceflight and other ground-based 
spaceflight analogs has indicated that immune functional changes can be expected 
from healthy individuals experiencing unexpected, potentially stressful conditions 
like spaceflight.   The reduced percentage of IFNγ producing T cell subsets observed 
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at BR+7 in the treatment group, but not the control group (figure 2C), may be an 
initial stress response to daily centrifugation.   The fact that this alteration corrects 
itself by BR+14 lends support to this idea.   There were no observed changes in the T 
cell function assessments for either treatment or control subjects (figures 2E and 2F).   
These data indicate that there was there no observable immune-related pathology 
during the bed rest phase for either subject group.  In addition, there was no other 
adverse effect on generalized immune function.   Thus, neither the 21 day bed rest nor 
the daily AG treatment appeared to adversely affect immunity. 
 
We have previously reported increase viral (EBV, VZV and CMV) reactivation 
during space flight as well as ground-based space analog studies (6).  In this study, 
though there was an increasing trend in the EBV reactivation during the 21day bed 
rest period in the subjects in both groups (EBV frequency 21%), these increases were 
not significantly different. It is interesting to note that VZV and CMV which are not 
shed in normal healthy subjects, showed a slight decrease in the subjects who had 
undergone AG treatment as compared to the control group suggesting that AG may 
help in lowering the CMV and VZV shedding in these subjects.  
 
In summary, our data suggest that stress associated with 21days of bed rest along with 
artificial gravity countermeasure did not have a major affect on the behavioral 
assessment scores, salivary cortisol and reactivation of EBV, CMV and VZV. 
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